NDLI: ANTICANCER ACTIVITY OF PYRIPLATIN, A MONOFUNCTIONAL CATIONIC PLATINUM(II) COMPOUND, IN HUMAN CANCER CELLS

Please wait, while we are loading the content...

Synthetic Triterpenoid Cyano Enone of Methyl Boswellate (CEMB) activates intrinsic, extrinsic, & endoplasmic reticulum stress cell death pathways in tumor cell lines

Nerve growth factor links oral cancer progression, pain, and cachexia

Human Monoclonal Antibody Fragments Binding to Insulin-like Growth Factors 1 and 2 with Picomolar Affinity

CARFILZOMIB INTERACTS SYNERGISTICALY WITH HISTONE DEACETYLASE INHIBITORS IN MANTLE CELL LYMPHOMA CELLS IN VITRO AND IN VIVO

Impact of APE1/Ref-1 Redox Inhibition on Pancreatic Tumor Growth

ANTICANCER ACTIVITY OF PYRIPLATIN, A MONOFUNCTIONAL CATIONIC PLATINUM(II) COMPOUND, IN HUMAN CANCER CELLS

Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells

Exon 11 skipping of E-cadherin RNA downregulates its expression in Head and Neck cancer cells

Year: 2011, Volume: 10, Issue: 8

Year: 2011, Volume: 10, Issue: 7

Year: 2011, Volume: 10, Issue: 6

Year: 2011, Volume: 10, Issue: 5

Year: 2011, Volume: 10, Issue: 4

Year: 2011, Volume: 10, Issue: 3

Year: 2011, Volume: 10, Issue: 2

Year: 2011, Volume: 10, Issue: 1

Year: 2010, Volume: 9

Year: 2009, Volume: 8

Year: 2008, Volume: 7

Year: 2007, Volume: 6

Year: 2006, Volume: 5

Year: 2005, Volume: 4

Year: 2003, Volume: 2

ANTICANCER ACTIVITY OF PYRIPLATIN, A MONOFUNCTIONAL CATIONIC PLATINUM(II) COMPOUND, IN HUMAN CANCER CELLS

Content Provider	PubMed Central
Author	Lovejoy, Katherine S. Serova, Maria Ivan, Bieche Emami, Shahin Maurizio, D'incalci Massimo, Broggini Erba, Eugenio Christian, Gespach Cvitkovic, Esteban Faivre, Sandrine Raymond, Eric Lippard, Stephen J.
Abstract	Pyriplatin (cis-diammine(pyridine)chloroplatinum(II) or cDPCP), a platinum-based antitumor drug candidate, is a cationic compound with anticancer properties in mice and is a substrate for the organic cation transporters, hOCT1 and hOCT2, which facilitate oxaliplatin uptake. Unlike cisplatin and oxaliplatin, which form DNA cross-links, pyriplatin binds DNA in a monofunctional manner. The antiproliferative effects of pyriplatin, as well as combintions of pyriplatin with known anticancer drugs (paclitaxel, gemcitabine, SN38, cisplatin or 5-fluorouracil), were evaluated in a panel of epithelial cancer cell lines, with direct comparison to cisplatin and oxaliplatin. The effects of pyriplatin on gene expression and platinum-DNA adduct formation were also investigated. Pyriplatin exhibited cytotoxic effects against human cell lines after 24 h (IC50: 171 – 443 μM), with maximum cytotoxicity in HOP-62 non-small cell lung cancer cells after 72 h (IC50: 24 μM). Pyriplatin caused a G2/M block of cell cycle similar to that induced by cisplatin and oxaliplatin. Apoptotic cell death was supported by Annexin-V analysis and detection of phosphorylated H2AX and Chk2. Treatment with pyriplatin caused an increase in CDKN1/p21 and decrease in ERCC1 mRNA expression. On a platinum-per-nucleotide basis, pyriplatin adducts resulted in less cytotoxicity than cisplatin- and oxaliplatin-DNA adducts. The mRNA levels of several genes implicated in drug transport and repair of DNA damage, including MSH2 and GSTP1, correlate with pyriplatin cellular activity in our panel of cell lines. Synergy was observed in combinations of pyriplatin with paclitaxel. Because it has a different spectrum of activitythan that of cisplatin or oxaliplatin, pyriplatin may be regarded as a lead compound for the development of other drug candidates with cytotoxicity profiles that differ from those of the drugs currently in use.
Related Links	http://dx.doi.org/10.1158/1535-7163.mct-11-0250
Ending Page	1719
Page Count	11
Starting Page	1709
File Format	PDF
ISSN	15357163
e-ISSN	15388514
Journal	Molecular cancer therapeutics
Issue Number	9
Volume Number	10
Language	English
Publisher Date	2011-09-01
Access Restriction	Open
Subject Keyword	Cancer Research Oncology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cancer Research Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Understanding and improving platinum anticancer drugs--phenanthriplatin.

CyclometalatedIminophosphorane Gold(III) and Platinum(II)Complexes. A Highly Permeable Cationic Platinum(II) Compound withPromising Anticancer Properties

A new anticancer platinum compound, (-)-(R)-2-aminomethyl-pyrrolidine(1,1-cyclobutanedicarboxylato) platinum(II): DNA interstrand crosslinking, repair and lethal effects in normal human, Fanconi's anaemia and xeroderma pigmentosum cells.

Monofunctional Platinum(II) Anticancer Agents

A new anticancer platinum compound, (–)-(R)-2-aminomethyl-pyrrolidine(1,1-cyclobutanedicarboxylato) platinum(II): DNA interstrand crosslinking, repair and lethal effects in normal human, Fanconi's anaemia and xeroderma pigmentosum cells

A new platinum(II) compound anticancer drug candidate with selective cytotoxicity for breast cancer cells

A new platinum(II) compound anticancer drug candidate with selective cytotoxicity for breast cancer cells

A new platinum(II) compound anticancer drug candidate with selective cytotoxicity for breast cancer cells

RNA-Seq Analysis of Cisplatin and The Monofunctional Platinum(II) Complex, Phenanthriplatin, in A549 Non-Small Cell Lung Cancer and IMR90 Lung Fibroblast Cell Lines

ANTICANCER ACTIVITY OF PYRIPLATIN, A MONOFUNCTIONAL CATIONIC PLATINUM(II) COMPOUND, IN HUMAN CANCER CELLS

Similar Documents

Understanding and improving platinum anticancer drugs--phenanthriplatin.

CyclometalatedIminophosphorane Gold(III) and Platinum(II)Complexes. A Highly Permeable Cationic Platinum(II) Compound withPromising Anticancer Properties

A new anticancer platinum compound, (-)-(R)-2-aminomethyl-pyrrolidine(1,1-cyclobutanedicarboxylato) platinum(II): DNA interstrand crosslinking, repair and lethal effects in normal human, Fanconi's anaemia and xeroderma pigmentosum cells.

Monofunctional Platinum(II) Anticancer Agents

A new anticancer platinum compound, (–)-(R)-2-aminomethyl-pyrrolidine(1,1-cyclobutanedicarboxylato) platinum(II): DNA interstrand crosslinking, repair and lethal effects in normal human, Fanconi's anaemia and xeroderma pigmentosum cells

A new platinum(II) compound anticancer drug candidate with selective cytotoxicity for breast cancer cells

A new platinum(II) compound anticancer drug candidate with selective cytotoxicity for breast cancer cells

A new platinum(II) compound anticancer drug candidate with selective cytotoxicity for breast cancer cells

RNA-Seq Analysis of Cisplatin and The Monofunctional Platinum(II) Complex, Phenanthriplatin, in A549 Non-Small Cell Lung Cancer and IMR90 Lung Fibroblast Cell Lines

ANTICANCER ACTIVITY OF PYRIPLATIN, A MONOFUNCTIONAL CATIONIC PLATINUM(II) COMPOUND, IN HUMAN CANCER CELLS